President & CEO
Dr. Jeffrey Stein is president, CEO and director of Cidara Therapeutics. Prior to joining Cidara, Jeffrey was CEO of Trius Therapeutics from 2007 until its acquisition by Cubist Pharmaceuticals in 2013. During his tenure, Trius developed the antibacterial drug tedizolid, which received marketing approval from the U.S. Food and Drug Administration in June 2014. Tedizolid is now marketed by Merck under the name Sivextro. Jeffrey currently serves as a director of Paratek Pharmaceuticals and Ideaya Biosciences. He is also founding chairman and president of the Antibiotics Working Group, an industry-leading 501(c)(6) organization. Previously, Jeffrey was a venture partner and Kauffman Fellow with Sofinnova Ventures and opened the firm’s San Diego office in 2005. His other prior roles include serving as co-founder and chief scientific officer of Quorex Pharmaceuticals (acquired by Pfizer) and principal scientist with Diversa Corporation and the Agouron Institute.